| ARB | adrenergic receptor binder |
|---|---|
| ARM | adrenergic receptor material; aerosol rebreathing method; ambulatory renal monitor; anorectal manome... |
| BAR | bariatrics; barometer, barometric; beta-adrenergic receptor |
| BARK | beta-adrenergic receptor kinase |
| BAS | balloon atrial septostomy; benzyl anti-serotinin; beta-adrenergic stimulation; boric acid solution |
β-adrenergic agent (
β-adrenergic receptor blocking agent (베타 아드레날린성 수용체 차단제
| adrenergic beta-agonists | Drugs that selectively bind to and activate beta-adrenergic receptors. (12 Dec 1998) |
|---|---|
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
| adrenergic bronchodilator | <pharmacology> A medication that acts to dilate (enlarge) the lumen of the airway to allow the unrestricted passage of air. These medications are commonly given to those with asthma who manifest wheezing. Examples include: theophylline, aminophylline, adrenaline, Alupent, metaproterenol, isoproterenol, Ventolin, Proventil, bitolterol, salmeterol, pirbuterol and albuterol. See: wheezing. (27 Sep 1997) |
| adrenergic fibres | Nerve fibres liberating catecholamines at a synapse after an impulse. (12 Dec 1998) |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| adrenergic receptors | Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents. Synonym: adrenoceptor, adrenoreceptors. (05 Mar 2000) |
| adrenergic uptake inhibitors | Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (12 Dec 1998) |
| alpha-adrenergic blocking agent | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
| alpha-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles. (05 Mar 2000) |
| beta-adrenergic blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| beta-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2). (05 Mar 2000) |
| receptors, adrenergic | Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction. (12 Dec 1998) |